An open-label, phase I/II trial of gemtuzumab ozogamicin in combination with zosuquidar in patients with CD33 positive acute myeloid leukemia
Latest Information Update: 05 Oct 2023
At a glance
- Drugs Gemtuzumab ozogamicin (Primary) ; Zosuquidar (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 01 Nov 2023 Results published in the Cancer Chemotherapy and Pharmacology
- 12 Mar 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Aug 2006 Status change